Chinese medicine formula particle market "hundreds of flowers in bloom" behind

recently, Tiansli announced that the company received approval from the Tianjin Municipal Drug Administration for its research and production of Chinese medicine formula particles and clinical use in medical institutions in Tianjin with Chinese medicine diagnosis and treatment subjects. This also means that Tiansli in Tianjin approved Chinese medicine formula particle qualification, the future is expected to create new growth.The company said that the Chinese medicine formula particle project after 5 years of research and development, the establishment of the cultivation, harvesting, processing, storage to drug production, sales of traceable quality assurance system. The approval of the production license of Chinese medicine formulation particles in Tianjin and the approval of clinical use in Chinese medicine clinics are expected to enrich the company's product structure and add new bright spots to the company's growth.Tian Shili also said in the announcement, the company also participated in the formulation of Chinese medicine formula particle industry standards, and set up a chinese medicine industry chain standard system, which will be the follow-up company's Chinese medicine formula particle sales to lay a solid quality and brand foundation.

1. Formula grain spring has reachedIn fact, in addition to Tianshili, Ealing Pharmaceuticals as early as December 2019 issued a notice that the company received approval from the Hebei Provincial Drug Administration on matters related to the company's Chinese medicine formula particles, agreed to the company's application to increase the number of 237 Chinese medicine formula particle varieties, as well as medical institutions in Hebei Province to carry out 646 kinds of Chinese medicine formula particles clinical research and use, trial period of one year.Previously, the Hebei Provincial Drug Administration has also agreed to Ling Pharmaceutical 409 kinds of Chinese medicine formula particles in Hebei Province, grade A and above hospitals to carry out clinical research, plus the newly approved 237 varieties, Toling pharmaceutical industry has been approved a total of 646 Chinese medicine formula particle varieties, and the scope of clinical research and use from the original "Hebei Province grade A and above hospitals" expanded to "Hebei Province medical institutions."It can be said that due to the advantages of Chinese medicine formula particles themselves, more and more patients will choose to buy formula particles. Now many county-level Chinese hospitals have not sold Chinese herbal medicine but only formula particles.In terms of policy, in recent years, the state advocates the development of Traditional Chinese medicine, in order to reduce the burden of patients in the future, it is expected that the high probability of formula particles can enter the national health insurance directory. This is a big good for large enterprises with strong capital and clear development direction, more and more Chinese medicine enterprises began to lay out the field of formula particles.

2. Head enterprises began to run awayIn November last year, the State Pharmacopeia Commission issued the "PublicIty on the Pilot Uniform Standards for Chinese Medicine Formula Particle Varieties", according to which, in accordance with the unified deployment requirements of the State Drug Administration, as of the end of May 2019, it had received a total of 437 studies on 301 varieties submitted by 14 production enterprises and one research institution. Through the organization of 12 expert review reviews, 160 varieties of which formed a pilot unified standard of the proposed publicity standards.The units providing the above-mentioned draft standards and research materials are: Guangdong One-Party Pharmaceutical Co., Ltd., Jiangyin Tianjiang Pharmaceutical Co., Ltd., Sichuan New Green Pharmaceutical Technology Development Co., Ltd., Beijing Kangrentang Pharmaceutical Co., Ltd., China Resources 39 Pharmaceutical Co., Ltd., Peili (Nanning) Pharmaceutical Co., Ltd., Shenwei Pharmaceutical Group Co., Ltd., Tianshili Pharmaceutical Group Co., Ltd. and Anhui Jiuzhou Fangyuan Pharmaceutical Co., Ltd.It can be concluded that in the competitive environment of the future Chinese medicine formulation particle market, the above-mentioned enterprises will take the lead position, and for the whole industry, it will also show the Matthew effect of Henghengqiang.In addition, it should be noted that the implementation of this "on the Chinese medicine formula particle varieties pilot unified standards of publicity", will also improve the quality standard construction of Chinese medicine formula particles, increase barriers to new entry, combat the illegal production of Chinese medicine formula particles small pharmaceutical enterprises, purify the market, but also for the Chinese medicine formula particles nationwide opening up laid the foundation.If the Chinese medicine formula particles are opened up throughout the country, the market space is expected to reach 80 billion yuan, that is, accounting for 35% of the market size of 220 billion Chinese medicine tablets.

3. There will still be uncertaintyOf course, it should also be noted that, for the time being, only Beijing, Zhejiang and other individual provinces and cities clear formula particles into health insurance, and Heilongjiang, Fujian and other provinces and cities clear formula particles are not included in the scope of medical insurance;In addition, there are some provinces to protect the province's enterprises, only the province's enterprises to produce particles into health insurance, such as in Hebei, only Shenwei Pharmaceutical production of particles in the scope of medical insurance.At present, the Chinese medicine formula particles 25% drug addition has been cancelled, although can be made up by high prescription prices, but this year, the Health Insurance Bureau on the issue of ticketing more rigorous investigation, will also affect some sales.At the same time, the current Chinese medicine formula particles do not occupy the proportion of drugs, but in the future whether to include the proportion of drugs, whether to follow the two-vote system, whether to reduce the price of comprehensive health insurance, and ultimately whether to collect? All these bring uncertainty to the chinese medicine formula particles. (Sina Pharmaceutical News)